about
sameAs
Neurotrophins and Neuropathic Pain: Role in PathobiologyComparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin A(2-17) following spinal and supraspinal routes of administrationOxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic painEvaluation of a High-Throughput Peptide Reactivity Format Assay for Assessment of the Skin Sensitization Potential of ChemicalsIn vitro methods for hazard assessment of industrial chemicals - opportunities and challengesLipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipationASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO.PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical modelsThe ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation.Differences between and combinations of opioids re-visited.In vivo high angular resolution diffusion-weighted imaging of mouse brain at 16.4 Tesla.Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenationPathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE modelsPain, analgesia and genetics.Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.Pregabalin for the treatment of fibromyalgia.Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: a mini review.Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies.Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere.Novel polymeric bioerodable microparticles for prolonged-release intrathecal delivery of analgesic agents for relief of intractable cancer-related pain.Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods.Topical application of a novel oxycodone gel formulation (tocopheryl phosphate mixture) in a rat model of peripheral inflammatory pain produces localized pain relief without significant systemic exposure.In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy.Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.Peripherally acting novel lipo-endomorphin-1 peptides in neuropathic pain without producing constipation.Synthesis and biological evaluation of an orally active glycosylated endomorphin-1.A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain.Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats.Morphine has a dual concentration-dependent effect on K(+)-evoked substance P release from rat peripheral airways.Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain.Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones.Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain.Pharmacokinetics of prazepam in man.
P50
Q28084413-3556F91D-85D4-4532-8CA6-0229FF397C8DQ28250964-3A5BC491-706C-419B-BC17-303D6BADE468Q28299786-AB495D8E-4C34-4732-85E7-1C92576E4382Q28389536-E19A84DC-CE50-4C06-84D9-AF34F63D4448Q28393171-5D41912A-08EA-4E1A-B00C-69127EC9E38BQ28482381-13838FBE-E2F7-4A5B-A8DE-601646439B1FQ34494688-37D1F697-1AE1-4EDA-9090-3A03779B0290Q34627931-7E94BDBF-76F2-4EF7-8CBC-37AC255D52E6Q34630847-ED50958C-EE57-4DA9-93A6-88A110685EC2Q34825123-4600B3A7-828D-424A-9BB7-BA81AD766C1DQ35674261-7EA1F5DB-2021-4F37-B976-B020B9D5F916Q36928231-ECABE86F-D05B-425A-86E3-B54B56F04FDAQ37187646-938C2BB1-C518-449C-8CE6-D18D099BEC47Q37399781-73E29ED4-7B20-4675-AB9D-19A050B8CB57Q37601317-900A6656-0741-4733-BFB8-E769D6F86A51Q37944353-62C3D9C3-8C46-4404-9327-C36A87379301Q38004165-8AA3963F-627B-479D-A9D0-6E42AB0FD1EDQ38020946-16E64E1C-8819-4FFA-9FD9-A9E282683132Q38220936-A93D553B-BE98-4EC0-B0DB-7739241F7C7AQ38260195-DCCB7BD3-2788-4411-921C-7C9A7324680AQ38702811-B2D001DF-8F38-427F-81B8-A21F877A235EQ38937456-E42AE93D-E749-435C-B55F-955219787D6BQ39004892-962CFA9C-3649-497A-A7E9-C55BAEDEB282Q39033886-DFFD9FD2-4DFF-4D5B-A439-D54056CABF43Q39128725-EB7329D3-B39C-41C7-8EF3-28360223D68DQ39180043-035A168D-46D3-49B8-B4F9-7E7F8FCB2559Q39189027-5258EFCD-5A21-49D8-BAE1-47174817D83EQ39209988-A18ADA1B-EAC4-48EE-AED6-DFEA79ADDFE4Q39211823-3E73E5D9-08EE-454B-BD34-E117AA6FB38BQ39230743-C1A63F98-D0B8-4483-9A30-71324E73D188Q39231754-5DB1A17B-D2D9-47BC-A3A6-895D5C4FDE1BQ39246595-E0AE1558-0F5C-4CEF-89F9-D15FC1B04DF8Q39294713-555C69CD-7CB1-46AA-87D2-6F085C228753Q39362180-4CD63267-6635-4BE2-8B80-277A9560DA80Q39432900-126CCC45-EAF0-45A5-A929-149D4E759FADQ39453713-71282EC0-4F43-4788-8B8A-FC0756B9E598Q39477430-5AF579EF-79BC-4AD3-BEF7-0049553F3C6DQ39655500-68BB0006-F004-4636-B52F-8E4A7150DF3CQ39723863-94247097-310B-4883-AB2A-E42638D280A0Q41118257-342873C2-57F1-401B-B60D-0B9B1F3B16F5
P50
description
Australian pharmacist
@en
apotheker uit Australië
@nl
cógaiseoir Astrálach
@ga
farmacéutica australiana
@es
pharmacist Australian
@en-ca
pharmacist Australian
@en-gb
صيدلية أسترالية
@ar
name
Maree Smith
@ast
Maree Smith
@en
Maree Smith
@es
Maree Smith
@ga
Maree Smith
@nl
Maree Smith
@sq
Maree T Smith
@sl
type
label
Maree Smith
@ast
Maree Smith
@en
Maree Smith
@es
Maree Smith
@ga
Maree Smith
@nl
Maree Smith
@sq
Maree T Smith
@sl
altLabel
Maree T Smith
@en
Maree T Smith
@nl
Maree T. Smith
@en
Maree Therese Smith
@en
prefLabel
Maree Smith
@ast
Maree Smith
@en
Maree Smith
@es
Maree Smith
@ga
Maree Smith
@nl
Maree Smith
@sq
Maree T Smith
@sl
P1053
I-4005-2015
P1153
55387899900
P166
P21
P2381
P27
P31
P3829
P496
0000-0003-2281-3734